Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | SLGC | Employee Stock Option (Right to Buy) | Sep 1, 2021 | Class A Common Stock, par value $0.0001 | 14K | $4.77 | Direct | F1, F2 | ||||||
holding | SLGC | Employee Stock Option (Right to Buy) | Sep 1, 2021 | Class A Common Stock, par value $0.0001 | 27.9K | $4.77 | Direct | F1, F2 | ||||||
holding | SLGC | Employee Stock Option (Right to Buy) | Sep 1, 2021 | Class A Common Stock, par value $0.0001 | 21K | $4.77 | Direct | F1, F2 | ||||||
holding | SLGC | Employee Stock Option (Right to Buy) | Sep 1, 2021 | Class A Common Stock, par value $0.0001 | 105K | $4.77 | Direct | F1, F2 | ||||||
holding | SLGC | Employee Stock Option (Right to Buy) | Sep 1, 2021 | Class A Common Stock, par value $0.0001 | 126K | $6.93 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
F2 | In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock (the "Exchange Ratio"). In addition, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards. |